|
Treatment related adverse events |
|||||
| Number (%) with outcome |
|||||
|
|
|||||
| Dosing (mg) |
Number of trials |
Sildenafil |
Placebo |
Relative risk (95% CI) |
NNH (95% CI) |
|
|
|||||
| 25 |
3 |
71/312 (23) |
33/426 (8) |
2.8 (1.9 to 4.2) |
6.7 (4.9 to 10) |
| 50 |
5 |
190/508 (37) |
59/607 (10) |
3.7 (2.8 to 4.8) |
3.6 (3.1 to 4.4) |
| 100 |
5 |
260/506 (51) |
59/607 (10) |
5.0 (3.9 to 6.5) |
2.4 (2.2 to 2.7) |
| 200 |
2 |
137/191 (72) |
26/181 (14) |
5.0 (3.5 to 7.2) |
1.7 (1.5 to 2.0) |
| Dose optimised |
5 |
155/517 (30) |
60/524 (11) |
2.6 (2.0 to 3.4) |
5.4 (4.3 to 7.3) |
Moore et al. BMC Urology 2002 2:6 doi:10.1186/1471-2490-2-6 |
|||||